Can Semaglutide Help Heart Failure Patients Who Also Have Obesity? | Research

The takeaway

The STEP-HFpEF trial showed semaglutide significantly improved quality of life, weight, exercise capacity, inflammation, and heart failure biomarkers in obese patients with heart failure with preserved ejection fraction.

30-40% CRP reduction
anti-inflammatory effect of semaglutide observed across STEP trials

What the researchers found

STEP-HFpEF trial: semaglutide significantly improved quality of life, weight, 6-minute walk distance, CRP (30-40% reduction), and NT-proBNP levels in 529 obese HFpEF patients over 52 weeks.

Why it matters

HFpEF is the most common form of heart failure and has lacked effective treatments beyond managing symptoms. Semaglutide may address the underlying obesity-inflammation axis driving HFpEF, representing a potential disease-modifying therapy.

The numbers in context

HFpEF is the majority of community heart failure. STEP trials showed 30-40% C-reactive protein reduction with semaglutide.

How the study worked

Narrative review summarizing key clinical trial evidence (STEP trials, STEP-HFpEF, SELECT) for GLP-1 agonists in obesity-related heart failure with preserved ejection fraction.

Who was studied

Patients with obesity-related heart failure with preserved ejection fraction

What this study cannot tell us

Review format without systematic methodology; STEP-HFpEF excluded diabetic patients; 52-week duration may not capture long-term outcomes; semaglutide's HFpEF benefits may be partially mediated through weight loss alone.

How to read the evidence

Strong evidence based on a randomized controlled trial (STEP-HFpEF, N=529) and supported by larger cardiovascular outcome trials (SELECT), synthesized in a narrative review.

When this study was published

Published in 2024, summarizing the most recent landmark trial data on semaglutide in heart failure.

The bigger picture

The intersection of obesity and heart failure affects millions worldwide. Semaglutide's demonstrated benefits across weight, inflammation, exercise capacity, and cardiovascular outcomes position GLP-1 agonists as potentially transformative for this large patient population.

Questions still open

Does semaglutide provide HFpEF benefits independent of weight loss, or is weight reduction the primary mechanism?
Will semaglutide benefit HFpEF patients who also have diabetes?
Can semaglutide reduce HFpEF hospitalization and mortality long-term?

Common questions

Can semaglutide actually help your heart if you have heart failure?

Yes — in the STEP-HFpEF trial, patients with heart failure and obesity who took semaglutide for a year showed significant improvements in quality of life, exercise ability, weight, and heart failure markers compared to placebo.

Is semaglutide's heart benefit just from weight loss?

Weight loss is part of it, but semaglutide also reduced inflammation markers (CRP) by 30-40%, suggesting direct anti-inflammatory effects that may benefit the heart beyond just losing weight.

Read the original research

Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.

European heart journal supplements : journal of the European Society of Cardiology, 26(Suppl 1), i127-i130

View on PubMed ↗Publisher’s paper ↗

Citation

Temporelli, Pier Luigi. (2024). Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.. European heart journal supplements : journal of the European Society of Cardiology, 26(Suppl 1), i127-i130. https://doi.org/10.1093/eurheartjsupp/suae011